MedTrace Logo

An Open Study to Assess the Robustness of the CRC749 Inhaler

NCT02474017 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2022-03-07

No results posted yet for this study

Summary

To confirm the robustness of the CRC749 inhaler.

Conditions

Interventions

DRUG

MGR001

Fluticasone Propionate / Salmeterol administered using CRC749 inhaler

DEVICE

CRC749 inhaler

Sponsors & Collaborators

  • Mylan Pharma UK Ltd.

    lead INDUSTRY

Principal Investigators

  • Richard Allan · Mylan Pharma UK Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474017 on ClinicalTrials.gov